{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:42:11Z","timestamp":1789148531888,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The management of patients with myelodysplastic syndrome (MDS) refractory to hypomethylating agents (HMAs) remains a challenge with few reliably effective treatments. Preclinical studies have shown that the inhibition of the nuclear export protein XPO1 causes nuclear accumulation of p53 and disruption of NF-\u03baB signaling; both of which are relevant targets for MDS. Selinexor is an XPO1 inhibitor with demonstrated efficacy in MDS patients. Herein, we report three patients with MDS refractory to HMAs, however, when selinexor and venetoclax were added to the treatment regimen, the patients achieved a complete response and a significant reduction in spleen size. All patients successfully underwent hematopoietic stem cell transplantation. These cases demonstrate that the combination therapy can achieve CR and significant reductions in spleen size, offering a promising therapeutic option for patients with limited treatment choices. Combination therapy would also offer a potential way for patients to bridge to transplantation. Formal evaluations of this regimen in patients with MDS refractory to HMAs may be meaningful.<\/jats:p>","DOI":"10.3389\/fonc.2024.1477697","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:26:25Z","timestamp":1734589585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports"],"prefix":"10.3389","volume":"14","author":[{"given":"Yunshuo","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlv","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xialoin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (Ontime): A randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pharmthera.2015.06.001","article-title":"Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (Crm1) protein","volume":"153","author":"Ishizawa","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0550-8","article-title":"A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30209-X","article-title":"Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: A single-centre, single-arm, phase 2 trial","volume":"7","author":"Taylor","year":"2020","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000359","article-title":"Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic Malignancies","volume":"4","author":"Fischer","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-607648","article-title":"Decitabine priming enhances the antileukemic effects of exportin 1 (Xpo1) selective inhibitor selinexor in acute myeloid leukemia","volume":"125","author":"Ranganathan","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of Aml in adults: 2022 recommendations from an international expert panel on behalf of the eln","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the us leukemia intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000016","article-title":"Beyond hypomethylating agents failure in patients with myelodysplastic syndromes","volume":"21","author":"Zeidan","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30383","article-title":"Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein Xpo1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-023-00422-1","article-title":"Role of innate immunological\/inflammatory pathways in myelodysplastic syndromes and Aml: A narrative review","volume":"12","author":"Vegivinti","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1266625","article-title":"The role of P53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications","volume":"58","author":"Zhang","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0351-2","article-title":"Tp53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1994.tb02382.x","article-title":"P53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia","volume":"145","author":"Kitagawa","year":"1994","journal-title":"Am J Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising sines for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.08.003","article-title":"Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease","volume":"1843","author":"Tran","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.06.013","article-title":"Therapeutic targeting of nuclear export inhibition in lung cancer","volume":"12","author":"Gupta","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0958-y","article-title":"Targeting nuclear import and export in hematological Malignancies","volume":"34","author":"Nachmias","year":"2020","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115","article-title":"Crm1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-121137","article-title":"Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via Nf-Kappab","volume":"111","author":"Yu","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e22423","DOI":"10.1371\/journal.pone.0022423","article-title":"Silencing nuclear pore protein Tpr elicits a senescent-like phenotype in cancer cells","volume":"6","author":"David-Watine","year":"2011","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-022-01319-y","article-title":"Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents","volume":"15","author":"Lee","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (Hmas) induce high response rates in Mds, including patients after Hma therapy failure","volume":"4","author":"Ball","year":"2020","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1775214","article-title":"Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: A retrospective evaluation of a real-world experience","volume":"61","author":"Azizi","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of Xpo1 enhances cell death induced by Abt-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","article-title":"Simultaneous targeting of Xpo1 and Bcl2 as an effective treatment strategy for double-hit lymphoma","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1091931","article-title":"Epigenetic priming with decitabine followed by low-dose idarubicin\/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms","volume":"57","author":"Ye","year":"2016","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1477697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:26:27Z","timestamp":1734589587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1477697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":37,"alternative-id":["10.3389\/fonc.2024.1477697"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1477697","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"article-number":"1477697"}}